News

Retatrutide : A triple agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and...

This individual buyer from Bosnia and Herzegovina is a bio-research enthusiast with a keen interest in the potential applications of peptide produc...

The blend peptides BPC 157 and TB500 leverages the advantages of both, offering broader application prospects. They synergistically act on injured ...

summary On October 24, 2025, Gelion announced the signing of a comprehensive cooperation agreement with TDK to jointly develop high-performance bat...

Recently, seven departments jointly issued the "Implementation Plan for Deepening the Innovation and Development of Service oriented Manufactu...

abstract Professor Wang Qingmin's research group at Nankai University has developed a novel difluorovinylsilane compound, which exhibits excell...

The four-day Hanover International Livestock Exhibition EuroTier will be held in Germany from November 12th to 15th. This is the world's larges...

As the world's first dual-target drug that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1...

Driven by the wave of globalization, competition in the biotechnology sector has intensified. As "star ingredients" in the biopharmaceutical and be...

As an improved fragment of human growth hormone (HGH), AOD 9604 , with its unique mechanism of regulating fat metabolism, has become a core breakth...

Retatrutide , as a novel triple agonist, is quietly transforming the daily landscape of obesity and diabetes treatment. This drug, which requires o...

To effectively manage fleas, which can be a real pain for pet owners, it's generally necessary to target every stage of the flea lifecycle-from...